Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | FABP4 | P15090 | 2/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | FABP3 | P05413 | 1/20 | 0.34 |
| ▸ | FABP2 | P12104 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL993855 | 0.80 | KCNH2 (0.44) | SLC6A2HTR2AHTR2CFABP4ALDH1A1 | |
| SCHEMBL4478439 | 0.76 | CDC7 (0.43) | ALDH1A1HTR6CDC7CDK2MAP3K14 | |
| SCHEMBL413823 | 0.75 | HTR2A (0.50) | SLC6A2HTR2AHTR2CROCK1HTR7 | |
| SCHEMBL30967900 | 0.75 | HTR2A (0.50) | SLC6A2HTR2AHTR2CROCK1HTR7 | |
| SCHEMBL984963 | 0.74 | ENPP3 (0.38) | — | |
| SCHEMBL6560789 | 0.72 | MCL1 (0.36) | SLC6A2HTR2AHTR2CROCK1MCL1 | |
| SCHEMBL4490724 | 0.71 | TFPI2 (0.38) | SLC6A2ALDH1A1MAPTTSHRRAB9A | |
| SCHEMBL18191223 | 0.70 | MAPT (0.41) | MCL1NPC1ALDH1A1TP53MAPT | |
| SCHEMBL4488558 | 0.70 | HTR2C (0.42) | SLC6A2HTR2AHTR2CROCK1HTR7 | |
| SCHEMBL4485147 | 0.70 | CDC7 (0.39) | HTR2AHTR2CROCK1HTR7NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673137-A1 | NBD1 MODULATORS AND METHODS OF USING THE SAME | Sionna Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12286424-B2 | Small molecule inhibitors of galectin-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-29 | — | — | US | disclosed |
| WO-2024182736-A1 | NBD1 MODULATORS AND METHODS OF USING THE SAME | SIONNA THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20230212158-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212158-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2023-07-06 | — | — | US | disclosed |
| EP-4149939-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | Bristol-Myers Squibb Company (US) | 2023-03-22 | — | — | EP | disclosed |
| CN-115551850-A | Small molecule inhibitors of galectin-3 | 百时美施贵宝公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2021231243-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-18 | — | — | WO | disclosed |
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-7754721-B2 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754721-B2 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090318493-A1 | Aryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
| EP-2061774-A2 | ARYLPIPERAZINE DERIVATIVES AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2009-05-27 | — | — | EP | disclosed |
| US-20080146607-A1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| WO-2008019971-A2 | ARYLPIPERAZINE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008019971-A2 | ARYLPIPERAZINE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045543-A1 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-02-21 | — | — | US | disclosed |
| US-20080045543-A1 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-02-21 | — | — | US | disclosed |
| US-20080045543-A1 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12286424-B2 | Small molecule inhibitors of galectin-3 | LGALS3, LGALS1, LGALS3BP | SLC6A2 4394/4885HTR2A 4484/4885HTR2C 4288/4885 |
| US-20230212158-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS1, LGALS3BP | SLC6A2 4394/4885HTR2A 4484/4885HTR2C 4288/4885 |
| US-20080146607-A1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | CNKSR1, RB1, AR | SLC6A2 4870/4885HTR2A 1967/4885HTR2C 1137/4885 |
| US-20090318493-A1 | Aryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | TPH2, TPH1, ADRA2C | SLC6A2 71/4885HTR2A 14/4885HTR2C 4/4885 |
| US-20080045543-A1 | Arylpiperazine derivatives and uses thereof | CYP3A7, CYP3A5, HTR7 | SLC6A2 1508/4885HTR2A 23/4885HTR2C 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.